In findings that challenge long-standing beliefs, researchers have shown that bilateral lung transplant may extend the lives of selected patients with stage IV non-small cell lung cancer (NSCLC). Experts stress, however, that no one is calling it a cure — and that only a small fraction of patients would be candidates.

In a single-center registry study, 1-year survival was 100% among 17 patients who underwent bilateral lung transplantation for stage IV NSCLC that was medically refractory and still confined to the lungs. That compared with a survival rate of 41% among 81 similarly eligible patients who received standard medical management alone.

The findings, published last week in JAMA, question the conventional wisdom that lung transplantation has no role in lung cancer treatment.

The approach may, in fact, offer “a new path forward” for carefully selected patients, according to lead researcher Ankit Bharat, MD, of Northwestern University Feinberg School of Medicine in Chicago.

At the same time, he and his colleagues cautioned that the universal 1-year survival should not be overinterpreted: 2 of the 17 patients have since died, and there is no indication that lung transplantation restores “normal life expectancy,” they reported.

Experts who were not involved in the study stressed that longer-term follow-up and validation in larger studies are needed before the approach can be more widely adopted.

A Rare Clinical Scenario

Most patients with stage IV NSCLC have disease that’s spread beyond the lungs, but for a small subset the cancer remains lung-limited. Those patients often die of respiratory failure, despite targeted therapies, immunotherapy, and other systemic treatments.

Historically, attempts at lung transplantation in patients with NSCLC have failed, with high recurrence rates and poor survival. However, cancer staging, therapies, and transplant surgery techniques have all evolved dramatically, and Bharat’s team reasoned that in carefully chosen patients, lung transplant may now be a better option than standard care.

To test that hypothesis, the researchers established the prospective DREAM study, tracking 404 patients across three cohorts.

The first cohort included 17 patients with medically refractory, lung-limited stage IV NSCLC who underwent lung transplantation. The second included 81 patients fitting the same eligibility criteria who did not undergo transplant because of nonmedical barriers and instead received standard care (best available systemic therapies or supportive care). The third cohort included 306 patients without cancer who underwent transplants for end-stage pulmonary disease.

Surgeons transplanting lungs in patients with NSCLC used dissemination-minimizing techniques, including early pulmonary vein control, removal of both lungs before implantation, and extensive airway irrigation.

The primary outcome was overall survival in the transplant group vs the medically managed group. The secondary outcome was 1-year survival post-transplant vs transplant recipients who did not have cancer.

‘Impressive’ Early Survival Data

One-year overall survival was 100% in the NSCLC transplant group compared with 40.8% among patients with lung cancer who received medical management alone — an absolute difference of 59.2 percentage points.

Similarly, survival free of cancer recurrence or progression at 1 year was 92.3% in the transplant group compared with just 5.6% among medically managed patients. At the most recent follow-up (January 31, 2026), 2 of the 17 patients with NSCLC who underwent lung transplantation had died.

Outcomes also proved noninferior compared with patients undergoing transplants for end-stage lung disease, whose 1-year post-transplant survival was 88%.

Mara Antonoff, MD, thoracic surgeon at The University of Texas MD Anderson Cancer Center in Houston, called the survival outcomes impressive, noting that the transplant recipients with lung cancer were in worse respiratory condition than the group who received medical management.

The study challenges “one of our long-held assumptions in thoracic oncology — that lung transplantation is fundamentally incompatible with advanced lung cancer,” Antonoff told Medscape Medical News.

Still, she stressed the need for longer follow-up, multicenter validation, and more clarity on recurrence patterns and patients’ quality of life post-transplant.

A Provocative Concept, With Caveats

The DREAM patients who received lung transplants not only had lung-limited cancer but were also unique in several other respects, as an accompanying editorial by Ece Cali Daylan, MD, PhD, and Ramaswamy Govindan, MD, of Washington University in St. Louis, St. Louis, points out.

The majority (59%) had never smoked; they were relatively young, with a median age of 61 years; and they had fewer comorbidities and a more indolent disease course than typical patients with advanced NSCLC.

The bottom line is that lung transplantation would be a viable option for only a small fraction of patients — likely fewer than 5%, said Gregory Riely, MD, PhD, thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York City.

For now, he told Medscape Medical News, the approach should only be pursued through clinical trials.

Riely also pointed out that, historically, there’s been concern that posttransplant immunosuppression might accelerate cancer growth — though there was no evidence of that in this study’s short follow-up period.

More broadly, the research raises questions around the allocation of scarce donor lungs. According to Daylan and Govindan, “the ethical implications are hard to ignore,” given that the long-term durability of transplantation for patients with lung cancer is unknown.

“Lung transplant operates within a zero-sum system,” they wrote. “Each organ allocated to a recipient is unavailable to another recipient.”

The longer-term data will be key, according to Antonoff. If the survival benefit is durable, she said, it “could ultimately redefine what may be possible for a very thoughtfully selected group of patients.”

The study was funded by the National Institutes of Health, and several co-authors disclosed relationships with AbbVie, Bristol Myers Squibb, AstraZeneca, and others. Antonoff and Riely reported no relevant financial relationships.